influenza
Osivax publishes positive results from trial of influenza vaccine candidate
July 15, 2025Research and Development Osivax, Vaccine, Virology, clinical trial, influenza, respiratory diseases
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
October 5, 2023Research and Development COVID-19, Immunology, Moderna, clinical trial, influenza, vaccines
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational combination vaccine against influenza and …
Lethal triple mix of winter viruses could “push NHS to breaking point”
July 15, 2021COVID-19, NHS, influenza
A report from the Academy of Medical Sciences has found that a lethal triple mix of COVID-19, influenza, and the …
Janssen agrees $780 million deal for authorisation of Cidara flu treatment
April 6, 2021Manufacturing and Production Janssen, cidara, influenza
Janssen has struck a deal worth up to $780 million with Cidara Therapeutics for exclusive worldwide rights to Cidara’s CD388 …
Roche’s influenza drug Xofluza gets EU approval
January 11, 2021Sales and Marketing EC, Roche, influenza
The European Commission (EC) has approved Roche’s Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 …
FDA expands approval of Genentech’s Xofluza for post-exposure prevention of influenza
November 24, 2020Manufacturing and Production, Sales and Marketing FDA, Xofluza, influenza
Genentech has secured FDA approval for Xofluza (baloxavir marboxil) for the post-exposure prevention of influenza in patients at least 12 …
First recombinant influenza vaccine approved in the European Union
November 20, 2020Medical Communications, Sales and Marketing Europe, influenza, pharma
The European Commission (EC) has just approved its first recombinant influenza vaccine for the European Union, awarding marketing authorisation to …
Nanovax’s seasonal flu vaccine meets Phase 3 endpoints and matches Sanofi’s Fluzone
March 24, 2020Manufacturing and Production, Research and Development NanoFlu, Nanovax, influenza, pharma
Nanovax has reported positive Phase 3 data for its vaccine NanoFlu, with the candidate meeting its primary endpoints in the …
New findings on influenza could help improve cancer treatments
March 20, 2020Manufacturing and Production, Medical Communications Cancer, cancer treatments, flu, flu treatments, influenza
A new study into how the body fights influenza could help improve cancer immunotherapies. Researchers at the Fox Chase Cancer …
FDA approves first adjuvanted quadrivalent flu vaccine in over-65s
February 24, 2020Sales and Marketing FDA, flu, influenza, pharma, seqirus
The FDA has just authorised its first adjuvanted quadrivalent influenza vaccine, it has been announced. Seqirus’ Fluad Quadrivalent (influenza vaccine, adjuvanted) …
Seqirus’ Audenz becomes first FDA-approved cell-based adjuvant influenza A vaccine
February 5, 2020Research and Development, Sales and Marketing FDA, influenza, pharma, seqirus
The FDA has just approved the first adjuvanted, cell-based vaccine for the prevention of influenza A (H5N1) in the US, …
27,000 chickens to be culled after UK bird flu outbreak
December 11, 2019Research and Development Bird Flu, Chicken Flu, Swin Flu, influenza, influenza b
A chicken farm in Suffolk has been confirmed by the British government to have cases of bird flu. 27,000 birds …
FDA approves Sanofi’s quadrivalent flu vaccine for over-65s
November 6, 2019Research and Development, Sales and Marketing FDA, Fluzone, Sanofi, flu, influenza, pharma
Sanofi’s quadrivalent influenza vaccine Fluzone High Dose has secured FDA approval in adult patients over the age of 65 for …
Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial
September 2, 2019Research and Development, Sales and Marketing Roche, Xofluza, flu, influenza, pharma
Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment …
Gilead buys Novartis’ herpes, flu and cold virus preclinical programmes
July 23, 2019Manufacturing and Production Gilead, Novartis, antivrial, deal, herpes, influenza, rhinovirus
Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
